N-[2-(4-Aminophenoxy)ethyl]-N-methyl-N-(2-pyridinyl)amine | 329249-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[2-(4-Aminophenoxy)ethyl]-N-methyl-N-(2-pyridinyl)amine
• 英文别名: N-[2-(4-Aminophenoxy)ethyl]-N-methyl-2-pyridinamine；N-[2-(4-aminophenoxy)ethyl]-N-methylpyridin-2-amine
• CAS: 329249-49-2
• 化学式: C₁₄H₁₇N₃O
• 分子量: 243.308
• InChiKey: RTSBUMZVVVMFCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  51.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Benzamide compounds as apo b secretion inhibitors
  申请人：——

  公开号：US20040058903A1

  公开（公告）日：2004-03-25

  The present invention relates to compounds of the formula (I) wherein R 1 and R 2 are each independently lower alkyl lower alkenyl, acyl, amino, lower alkoxy, lower cycloalkyloxy, aryl, aryloxy, sulfooxy, mercapto, sulfo, hydrogen, halogen, nitro, cyano or hydroxy, or may form a ring structure; Q 1 is N or CH; L is optionally substituted unsaturated 3 to 10-membered heterocyclic group; X is optionally substituted monocyclic arylene or monocyclic heteroarylene; Y is -(A 1 ) m -(A 2 ) n -(A 4 ) k -; Z is directbond, —CH2-, —NH— or —O—; and R is hydrogen or lower alkyl, or a salt thereof The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  本发明涉及式(I)的化合物，其中R1和R2分别独立地为较低的烷基较低的烯基、酰基、氨基、较低的烷氧基、较低的环烷氧基、芳基、芳氧基、磺氧基、巯基、磺基、氢、卤素、硝基、氰基或羟基，或者可以形成环结构；Q1为N或CH；L是可选的取代的不饱和的3到10元杂环基；X是可选的取代的单环芳基或单环杂芳基；Y是-(A1)m-(A2)n-(A4)k-；Z是直键，-CH2-，-NH-或-O-；R为氢或较低的烷基，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于载脂蛋白B循环水平升高而导致的疾病或症状的药物。
• Ether and amide compounds and preparation of thereof as antidiadetics.
  申请人：——

  公开号：US20010008898A1

  公开（公告）日：2001-07-19

  Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. 1 (with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is 2 then n is 1 or 2. R 3 is OH—, CH 3 SO 2 NH—, CF 3 SO 2 NH—, CH 3 SO 2 NHCH 2 —, CF 3 SO 2 NHCH 2 —, HOOC—, CH 3 OOC—, 3 HOOC—CH 2 SO 2 NH—, CF 3 —CH 2 SO 2 NH—, 4 R 8 —NHSO 2 —, R 8 —NHSO 2 —CH 2 —, HOOC—CH 2 —O—, HSO 3 N═CH—, or R 9 —SO 2 NHCO—; R 4 is H, OH, O-alkyl or O—CH 2 OCH 3 ; R 5 is H, halogen atom, —CH 2 COOH or OH; R 6 and R 7 are hydrogen, t-butyl or pyrolidyl; R 8 is hydrogen or lower alkyl; R 9 is alkyl or thienyl; R 10 is lower alkyl) or a pharmaceutically acceptable salt.

  乙醚和酰胺衍生物被披露，其由以下式(I)及其药用可接受盐所代表，并且对于糖尿病的治疗是有用的。 1 （在以下情况下，附加条件为：(i) 当A为—O—时，n为2或3 (ii) 当A为 2 时，n为1或2。R 3 为OH—，CH 3 SO 2 NH—，CF 3 SO 2 NH—，CH 3 SO 2 NHCH 2 —，CF 3 SO 2 NHCH 2 —，HOOC—，CH 3 OOC—， 3 HOOC—CH 2 SO 2 NH—，CF 3 —CH 2 SO 2 NH—， 4 R 8 —NHSO 2 —，R 8 —NHSO 2 —CH 2 —，HOOC—CH 2 —O—，HSO 3 N═CH—，或R 9 —SO 2 NHCO—； R 4 为H，OH，O-烷基或O—CH 2 OCH 3 ； R 5 为H，卤原子，—CH 2 COOH或OH； R 6 和R 7 为氢，叔丁基或吡咯烷基； R 8 为氢或较低烷基； R 9 为烷基或噻吩基； R 10 为较低烷基） 或药用可接受盐。
• BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1326835A1

  公开（公告）日：2003-07-16
• [EN] BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS<br/>[FR] COMPOSÉS À BASE DE BENZAMIDE, INHIBITEURS DES SÉCRÉTIONS D'APOLIPOPROTÉINE B
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002028835A1

  公开（公告）日：2002-04-11

  The present invention relates to compounds of the formula (I) wherein R1 and R2 are each independently lower alkyl, lower alkenyl, acyl, amino, lower alkoxy, lower cycloalkyloxy, aryl, aryloxy, sulfooxy, mercapto, sulfo, hydrogen, halogen, nitro, cyano or hydroxy, or may form a ring structure; Q1 is N or CH; L is optionally substituted unsaturated 3 to 10-membered heterocyclic group; X is optionally substituted monocyclic arylene or monocyclic heteroarylene; Y is -(A1)m-(A2)n-(A4)k-; Z is direct bond, -CH2-, -NH- or -O-; and R is hydrogen or lower alkyl, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.
• [EN] SUBSTANTIALLY PURE ROSIGLITAZONE HYDROGEN SULFATE<br/>[FR] HYDROGÉNOSULFATE DE ROSIGLITAZONE ESSENTIELLEMENT PUR
  申请人：ACTAVIS GROUP PTC EHF

  公开号：WO2010013141A2

  公开（公告）日：2010-02-04

  Provided herein are impurities of rosiglitazone hydrogen sulfate, 4-[2-(N-methyl-2-(N- pyridinyl)amino)ethoxy]bromobenzene (bromo impurity) and 5-[[4-[2-[methyl-(2-pyridinyl- N-oxide)amino]ethoxy]phenyl]methyl]-2,4-thiazolidinedione (N-oxide impurity), and processes for preparing and isolating thereof. Provided further herein is a highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities, process for the preparation thereof, and pharmaceutical compositions comprising highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities.